Acknowledgements
The authors thank the participants and their families and all GB1211 study team members and investigators. GB1211 is being developed by Galecto Biotech AB. Authors employed by Galecto Biotech AB participated in the design, study conduct, analysis, and interpretation of data, as well as the writing, review, and approval of the manuscript. Third-party medical writing assistance under the direction of R.J.S was provided by Sinéad Holland PhD of Ashfield MedComms, an Ashfield Health company, and was funded by Galecto Biotech AB.